Publications
PEER REVIEWED ORIGINAL CONTRIBUTIONS
Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus DM, Bander NH. Anti-Prostate Specific Membrane Antigen-based Radioimmunotherapy for Prostate Cancer. Cancer 2010; 116(4 suppl): 1075-83.
Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, Nanus DM, Giannakakou PA, Kirby BJ. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip 2010; 10: 27-29.
Jeske S, Tagawa ST, Olowokure O, Selzer J, Giannakakou P, Nanus DM. Carboplatin Plus Paclitaxel Therapy after Docetaxel in Men with Metastatic Castrate Resistant Prostate Cancer. Urol Oncol 2010 May 5; E pub ahead of print
Tagawa ST, Milowsky MI, Jeske S, Mazumdar M, Kung S, Sung M, Lehrer D, Matulich D, Selzer J, Wright JJ, Nanus DM. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma (New York Cancer Consortium trial NCI 6981). Am J Clin Oncol 2010; in press
Beltran H, Robinson BD, Tagawa ST. Primary Squamous Cell Carcinoma of the Urinary Bladder Presenting as Peritoneal Carcinomatosis. Adv Urol 2010; in press
Tagawa ST, Dorff TB, Rochanda L, Ye W, Boyle S, Raghavan D, Lieskovsky G, Skinner DG, Quinn DI, Liebman HA. Subclinical hemostatic activation and surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU Int 2008 Jul 29; 102(9): 1086-91
Tagawa ST, Cheung E, Banta W, Gee C, Weber JS. Survival analysis after resection of metastatic disease followed by peptide vaccines in stage IV melanoma. Cancer 2006; 106: 1353-7.
Israel V*, Tagawa ST*, Snyder T, Jeffers S, Raghavan D. Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer. Investigational New Drugs 2004; 22: 291-297.
Tagawa ST, Lee P, Snively J, Boswell W, Ounparseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS. Phase I study of intranodal delivery of a plasmid DNA vaccine for stage IV melanoma. Cancer 98: 144-154, 2003.
INVITED CONTRIBUTIONS
Tagawa ST. Commentary on: “Sequential use of sorafenib and sunitinib in a series of 90 consecutive patients with renal cell carcinoma”. J Urol July 2009; 182:34.
Tagawa ST. Commentary on: “Adjuvant chemotherapy for high-risk upper tract urothelial carcinoma: Results from the Upper Tract Urothelial Carcinoma Consortiuim”. J Urol September 2009;182: 906.
Tagawa ST. Commentary on: "Phase II trial of paclitaxel, carboplatin, and gemcitabine in patients with locally advanced carcinoma of the bladder". J Urol 2008; Oct 16 [E pub ahead of print]
Arnason J, Tagawa ST, Bander NH. New and newer vascular targets in oncology. Commentary on "Molecular Targets on Blood Vessels for Cancer Therapies in Clinical Trials". Oncology 2007; 21: 1376-80.
Tagawa ST. Thrombosis in cancer: A review of epidemiology, plasma markers of hemostatic activation, fibrinolysis, and angiogenesis, and the potential use of heparins. Recent Res Devel Cancer 2004; 6(2): 295-310.
BOOKS AND CHAPTERS IN BOOKS
Tagawa ST, Hamid O, Skinner E, Kumar P. Uncommon Cancers of the Prostate. In Textbook of Uncommon Cancers, 3rd Ed. Raghavan D et al. Eds. Wiley & Sons, Ltd, 2006.
